Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
McKinsey
Boehringer Ingelheim
Mallinckrodt
McKesson

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR BRAVELLE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Bravelle

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00680238 ↗ Pregnancy/Implantation Rates Using a Day 3 Score Versus Graduated Embryo Score Plus a Biochemical Marker (sHLA-G) Completed University of Stellenbosch N/A 2004-06-01 Objective: To compare pregnancy rates and implantation rates when embryos are selected based on a single Day 3 (D.3) score vs. a GES score plus sHLA-G expression.
NCT00971152 ↗ Effect of a Higher Than Maximum 450IU Gonadotropin Dose in an In-vitro Fertilization Cycle Completed Ferring Pharmaceuticals Phase 3 2009-09-01 This goal of this study is to evaluate the outcomes from in vitro fertilization cycles where a 450 IU daily dose of gonadotropins is administered compared to those where a 600 IU daily dose is administered for women who are at risk of a poor ovarian response in order to determine if one dose or the other results in improved cycle outcomes.
NCT00971152 ↗ Effect of a Higher Than Maximum 450IU Gonadotropin Dose in an In-vitro Fertilization Cycle Completed Clinique Ovo Phase 3 2009-09-01 This goal of this study is to evaluate the outcomes from in vitro fertilization cycles where a 450 IU daily dose of gonadotropins is administered compared to those where a 600 IU daily dose is administered for women who are at risk of a poor ovarian response in order to determine if one dose or the other results in improved cycle outcomes.
NCT00971152 ↗ Effect of a Higher Than Maximum 450IU Gonadotropin Dose in an In-vitro Fertilization Cycle Completed OVO R & D Phase 3 2009-09-01 This goal of this study is to evaluate the outcomes from in vitro fertilization cycles where a 450 IU daily dose of gonadotropins is administered compared to those where a 600 IU daily dose is administered for women who are at risk of a poor ovarian response in order to determine if one dose or the other results in improved cycle outcomes.
NCT01354886 ↗ Single Dose FSH-GEX™ in Healthy Volunteers Completed Glycotope Biotechnology GmbH Phase 1 2011-04-01 The aim of the current study was the pharmacokinetic and pharmacodynamic characterization of a single dose administration of four doses of FSH-GEX™ in healthy pituitary-suppressed female volunteers, in comparison with two marketed comparator products.
NCT01354886 ↗ Single Dose FSH-GEX™ in Healthy Volunteers Completed Glycotope GmbH Phase 1 2011-04-01 The aim of the current study was the pharmacokinetic and pharmacodynamic characterization of a single dose administration of four doses of FSH-GEX™ in healthy pituitary-suppressed female volunteers, in comparison with two marketed comparator products.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Bravelle

Condition Name

Condition Name for Bravelle
Intervention Trials
Female Infertility 2
Infertility 2
Female Infertility Due to Diminished Ovarian Reserve 1
Male Infertility 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Bravelle
Intervention Trials
Infertility 7
Infertility, Female 3
Oligospermia 1
Infertility, Male 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Bravelle

Trials by Country

Trials by Country for Bravelle
Location Trials
United States 8
Netherlands 2
Canada 1
Spain 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Bravelle
Location Trials
New York 1
Washington 1
Texas 1
Maryland 1
Illinois 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Bravelle

Clinical Trial Phase

Clinical Trial Phase for Bravelle
Clinical Trial Phase Trials
Phase 4 1
Phase 3 2
Phase 1/Phase 2 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Bravelle
Clinical Trial Phase Trials
Completed 5
Enrolling by invitation 1
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Bravelle

Sponsor Name

Sponsor Name for Bravelle
Sponsor Trials
Ferring Pharmaceuticals 2
Glycotope Biotechnology GmbH 2
Glycotope GmbH 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Bravelle
Sponsor Trials
Industry 8
Other 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Johnson and Johnson
AstraZeneca
Dow
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.